Clinical Trials › NCT04530318
Active, Not RecruitingPhase 2
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis
Sponsored by Judit Pich
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 45
Target enrollment
Jan 2020
Start date
Mar 2026
Expected completion
Interventions / Treatments
Autologous peripheral blood differentiated adult tolerogenic dendritic cells expandedPlacebo
Conditions studied
Relapsing-Remitting Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.